Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (61-70 of 457) with videos related to

Pageof 46
Sort By:
Diabetes, Obesity & Metabolism|June 30, 2017
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetesElizabeth M Garry, John B Buse, Jennifer L Lund, et al.
Diabetes Care|April 6, 2018
The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. AdultsJin-Liern Hong, John B Buse, Michele Jonsson Funk, et al.
Diabetes Care|June 22, 2026
Comment on Nieman and Muniyappa Unmasking Hypercortisolism in Difficult-to-Control Type 2 Diabetes: A Useful Paradigm Shift?Yehuda Handelsman, Vivian Fonseca, John B Buse, et al.
Diabetes Care|January 22, 2020
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920Michael A Nauck, Eskil Kreiner, Søren Rasmussen, et al.
Diabetes, Obesity & Metabolism|April 8, 2021
Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100Anastasia-Stefania Alexopoulos, Andreas Andersen, Anders Meller Donatsky, et al.
American Journal of Epidemiology|June 13, 2025
High-dimensional Iterative Causal Forest (hdiCF) for Subgroup Identification Using Health Care Claims DataTiansheng Wang, Virginia Pate, Richard Wyss, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 20, 2019
Glucose-Responsive Insulin and Delivery Systems: Innovation and TranslationJinqiang Wang, Zejun Wang, Jicheng Yu, et al.
Diabetes Care|June 16, 2018
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER ExperienceBernard Zinman, Steven P Marso, Erik Christiansen, et al.
Diabetes Care|December 12, 2018
Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting SystemTiansheng Wang, Wenchao Lu, Huilin Tang, et al.
Pageof 46

Showing results (61-70 of 457) with videos related to

Sort By:
Pageof 46
Diabetes, Obesity & Metabolism|June 30, 2017
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetesElizabeth M Garry, John B Buse, Jennifer L Lund, et al.
Diabetes Care|April 6, 2018
The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. AdultsJin-Liern Hong, John B Buse, Michele Jonsson Funk, et al.
Diabetes Care|June 22, 2026
Comment on Nieman and Muniyappa Unmasking Hypercortisolism in Difficult-to-Control Type 2 Diabetes: A Useful Paradigm Shift?Yehuda Handelsman, Vivian Fonseca, John B Buse, et al.
Diabetes Care|January 22, 2020
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920Michael A Nauck, Eskil Kreiner, Søren Rasmussen, et al.
Diabetes, Obesity & Metabolism|April 8, 2021
Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100Anastasia-Stefania Alexopoulos, Andreas Andersen, Anders Meller Donatsky, et al.
American Journal of Epidemiology|June 13, 2025
High-dimensional Iterative Causal Forest (hdiCF) for Subgroup Identification Using Health Care Claims DataTiansheng Wang, Virginia Pate, Richard Wyss, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
Advanced Materials (Deerfield Beach, Fla.)|August 20, 2019
Glucose-Responsive Insulin and Delivery Systems: Innovation and TranslationJinqiang Wang, Zejun Wang, Jicheng Yu, et al.
Diabetes Care|June 16, 2018
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER ExperienceBernard Zinman, Steven P Marso, Erik Christiansen, et al.
Diabetes Care|December 12, 2018
Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting SystemTiansheng Wang, Wenchao Lu, Huilin Tang, et al.
Pageof 46